Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia
Gudiol, Carlota; Royo-Cebrecos, Cristina; Abdala, Edson; Akova, Murat; Alvarez, Rocio; Maestro-de la Calle, Guillermo; Cano, Angela; Cervera, Carlos; Clemente, Wanessa T.; Martin-Davila, Pilar; Freifeld, Alison; Gomez, Lucia; Gottlieb, Thomas; Gurgui, Merce; Herrera, Fabian; Manzur, Adriana; Maschmeyer, Georg; Meije, Yolanda; Montejo, Miguel; Peghin, Maddalena; Rodriguez-Bano, Jesus; Ruiz-Camps, Isabel; Sukiennik, Teresa C.; Tebe, Cristian; Carratala, Jordi
Publicación: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
2017
VL / 61 - BP / - EP /
abstract
beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
MENTIONS DATA
Publicaciones similares en Pharmacology & Toxicology
